- Title
- Preliminary analysis of potential drug and gene interactions involving tricyclic antidepressant drugs
- Creator
- Biswas, Mohitosh; Dias, Thilani H.; Daneshi, Nilofar; Holliday, Elizabeth; Hancock, Stephen; Attia, John; Scott, Rodney; Newby, David; Kerr, Karen P.; Milward, Elizabeth A.
- Relation
- 5th Annual International Conference on Pharmacology and Pharmaceutical Sciences (PHARMA 2017). Proceedings of the 5th Annual International Conference on Pharmacology and Pharmaceutical Sciences (PHARMA 2017) (Singapore 25-27 September, 2017) p. 8-13
- Publisher Link
- http://dx.doi.org/10.5176/2345-783X_PHARMA17.17
- Publisher
- Global Science and Technology Forum (GSTF)
- Resource Type
- conference paper
- Date
- 2017
- Description
- Abstract. Tricyclic antidepressants are frontline treatments for depression worldwide but can have many serious side effects. The safety and efficiency of these drugs may be affected by both drug-drug and drug-gene interactions. The objective of the present study was to investigate the community prevalence of predicted drug and gene interactions for tricyclic anti-depressant drugs in a cohort of older Australians from the Hunter Community Study. Participants were genotyped using Affymetrix Kaiser Axiom arrays or imputation from HapMap 2 and 1000 Genome reference panels. Of 57 participants on tricyclic antidepressants, 47 (83%) were co-prescribed at least one potential interacting drug, with on average 2.5 possible interactions per participant. Genotype data were available for 32 of the 57 participants taking tricyclic antidepressant drugs. Of these 32, 22% had clinically actionable genotypes predicted to increase the likelihood of adverse effects. A change of tricyclic antidepressant dose would be recommended for patients with these genotypes under current international pharmacogenomic guidelines. The findings of this study suggest that over 1 in 5 patients on tricyclic antidepressants may be at increased risk of adverse reactions involving drug-gene interactions that may justify dose reduction and emphasize the potential value of considering the pharmacogenomics of tricyclic anti-depressants in conjunction with drug interaction analyses.
- Subject
- drug interaction; gene interaction; pharmacogenomics; precision medicine; tricyclic antidepressants
- Identifier
- http://hdl.handle.net/1959.13/1387983
- Identifier
- uon:32703
- Identifier
- ISSN:2345-783X
- Language
- eng
- Reviewed
- Hits: 9572
- Visitors: 3839
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|